A meta-analysis on the safety of combination therapy with fenofibrate and statins / 中华心血管病杂志
Chinese Journal of Cardiology
; (12): 1063-1068, 2013.
Article
in Zh
| WPRIM
| ID: wpr-356454
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>The aim of this study was to assess the safety of fenofibrate-statin combination therapy.</p><p><b>METHODS</b>Medline, Cochrane Library, Web of Knowledge and CNKI were searched for 2184 randomized controlled trials. Finally, twenty-six studies with a total of 9494 participants were included in this analysis.</p><p><b>RESULTS</b>Compared with statins group, the fenofibrate-statin group had significantly higher incidence of aminotransferase elevations (OR 1.67, 95%CI 1.22-2.30, P < 0.05) . The two groups had identical incidence of creatin kinase elevations (OR 0.86, 95%CI 0.62-1.20, P > 0.05) , muscle-associated adverse events (OR 0.98, 95%CI 0.88-1.09, P > 0.05) and withdrawals due to hepatotoxicity or muscle toxicity. The safety of fenofibrate + standard-dose statin regimens were similar to those in fenofibrate-statin group.</p><p><b>CONCLUSION</b>Combined fenofibrate-statin treatment is generally safe and well tolerated, liver function should be monitored before and during and after therapy.</p>
Full text:
1
Database:
WPRIM
Main subject:
Fenofibrate
/
Randomized Controlled Trials as Topic
/
Combined Modality Therapy
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Therapeutic Uses
/
Hypolipidemic Agents
Type of study:
Clinical_trials
/
Systematic_reviews
Limits:
Adult
/
Aged
/
Aged80
/
Humans
/
Male
Language:
Zh
Journal:
Chinese Journal of Cardiology
Year:
2013
Document type:
Article